Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US45256X1037
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG007T9DYW9
IBRX
Immunitybio Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Immunitybio Inc
ISIN
US45256X1037
TICKER
IBRX
MIC
XNAS
REUTERS
IBRX.OQ
BLOOMBERG
IBRX US
Fri, 03.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       ImmunityBio
US45256X1037

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 26, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026, inclusive (the “C...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       ImmunityBio
US45256X1037

Did you buy IBRX securities between January 19, 2026, and March 24, 2026?Affected IBRX Investor SummaryWho: ImmunityBio, Inc. (NASDAQ: IBRX)What: Securities fraud class action lawsuit filedClass Period: January 19, 2026 through March 24, 2026Deadline to Seek Lead Plaintiff Status: May 26, 2026Key Lawsuit Allegations: Material misstatements and/or...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       ImmunityBio
US45256X1037

LOS ANGELES, April 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Sharehold...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       ImmunityBio
US45256X1037

LOS ANGELES, April 3, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       ImmunityBio
US45256X1037

Law Offices of Howard G. Smith reminds investors of the upcoming May 26, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       ImmunityBio
US45256X1037

SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 1, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 01.04.2026       ImmunityBio
US45256X1037

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026, inclusive (...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       ImmunityBio
US45256X1037

Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRANEW YORK, April 1, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ImmunityBio, Inc. (NASDAQ: IBRX) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between January 19, 2026 and March 24, 2026. IBRX shares fell $1...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       ImmunityBio
US45256X1037

Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against ImmunityBio, Inc. (ImmunityBio) (NASDAQ: IBRX) on behalf of those who purchased or acquired ImmunityBio securities between January 19, 2026, and March 2...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       ImmunityBio
US45256X1037

LOS ANGELES, April 1, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - March 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"). A class action lawsuit ha...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

Institutional investors holding positions in ImmunityBio, Inc. (NASDAQ: IBRX) during the period January 19, 2026 through March 24, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Shares lost $1.98 per share, a 21% decline, after an FDA Warning Letter exposed allegedly false promotional claims about the C...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

SAN DIEGO, March 31, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), have until May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). ImmunityBio investors have until May 26, 2026 t...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). ImmunityBio investors have until May 26, 2026 to file a lead plaintiff moti...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - March 31, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, inclus...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 31.03.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

NEW YORK, March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during the class period listed are encouraged to co...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced it has secured $75 million in non-dilutive financing under its existing Royalty Interest Purchase Agreement (RIPA) with Oberland Capital, increasing the total committed capital under the Agreement to $375 million. The amended agreemen...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - March 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"). A class action lawsuit ha...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) (“ImmunityBio” or the “Company”), if they purc...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       ImmunityBio
US45256X1037

SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       ImmunityBio
US45256X1037

Boston, Massachusetts--(Newsfile Corp. - March 30, 2026) - Block & Leviton announces that a securities fraud lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) and certain of its executives. Investors who have lost money in their ImmunityBio investment should contact the firm to learn more about how they might recover those losses....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       ImmunityBio
US45256X1037

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON IM...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       ImmunityBio
US45256X1037

Law Offices of Howard G. Smith announces an investigation on behalf of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IMMUNITYBIO, INC. (IBRX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALL...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sun, 29.03.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - March 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"). A class action lawsuit ha...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sun, 29.03.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi p...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sun, 29.03.2026       ImmunityBio
US45256X1037

The DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of IBRX during t...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sun, 29.03.2026       ImmunityBio
US45256X1037

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 28.03.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"). A class action lawsuit ha...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 28.03.2026       ImmunityBio
US45256X1037

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2025, both dates inclusive (the “Class Period”), have until May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio class action lawsuit. Cap...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       ImmunityBio
US45256X1037

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) securities during the period of January 19, 2026 through March 24, 2026, inclusive (“the Class Period”). If you suffered a loss on your ImmunityBio investmen...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       ImmunityBio
US45256X1037

NEW YORK, March 27, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 1...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       ImmunityBio
US45256X1037

The Law Offices of Frank R. Cruz announces an investigation of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON IMMUNITYBIO, INC. (IBRX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAI...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. This press...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       ImmunityBio
US45256X1037

SAN DIEGO, March 27, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2025, inclusive (the "Class Period"), have until May 26, 2026 to seek appointment as lead plaintiff of the Immuni...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"). A class action lawsuit ha...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       ImmunityBio
US45256X1037

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, emai...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       ImmunityBio
US45256X1037

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for ImmunityBio investors under the federal secur...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       ImmunityBio
US45256X1037

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced that based on the Independent Data Monitoring Committee (IDMC) review of the interim data, the committee recommended that the study is adequately powered to detect the pre-specified clinically meaningful difference in complete respons...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.03.2026       ImmunityBio
US45256X1037

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX) resulting from allegations that ImmunityBio, Inc. may have issued materially misleading business information to the investing public. So What: If you purchased ImmunityBio...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       ImmunityBio
US45256X1037

San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ImmunityBio, Inc. (NASDAQ: IBRX). The investigation focuses on ImmunityBio executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased ImmunityBio securiti...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People’s Republic of China has granted regulatory approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln). The approval establishes ANKTIVA’s initial presence in Asia and reflects the Company’...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.03.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive Cancer Network (NCCN®) has updated its 2026 NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer to include ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the t...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 13.03.2026       ImmunityBio
US45256X1037

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, reproducible, and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy platform....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink